Cellectar Biosciences 将来の成長

Future 基準チェック /06

Cellectar Biosciencesは、55%と59.5%でそれぞれ年率55%で利益と収益が成長すると予測される一方、EPSはgrowで63%年率。

主要情報

55.0%

収益成長率

62.98%

EPS成長率

Biotechs 収益成長	23.1%
収益成長率	59.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	10 Mar 2026

今後の成長に関する最新情報

Recent updates

Late Stage Radiopharmaceutical Catalyst And Global IP Platform Will Transform Future Cancer Treatment Prospects

Apr 04Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies based on its phospholipid drug conjugate platform for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?

Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve

Mar 20Catalysts About Cellectar Biosciences Cellectar Biosciences is a radiopharmaceutical company focused on phospholipid drug conjugates for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?

Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook

Mar 05Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies for difficult to treat cancers using its proprietary phospholipid drug conjugate platform. What are the underlying business or industry changes driving this perspective?

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Aug 08

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Aug 23

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Oct 05

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

May 20

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nov 30

業績と収益の成長予測

NasdaqCM:CLRB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	55	-12	N/A	N/A	3
12/31/2027	11	-28	N/A	N/A	3
12/31/2026	N/A	-29	N/A	N/A	3
12/31/2025	N/A	-22	-23	-23	N/A
9/30/2025	N/A	-19	-30	-30	N/A
6/30/2025	N/A	-29	-35	-35	N/A
3/31/2025	N/A	-25	-44	-44	N/A
12/31/2024	N/A	-45	-48	-48	N/A
9/30/2024	N/A	-50	-47	-46	N/A
6/30/2024	N/A	-53	-46	-45	N/A
3/31/2024	N/A	-62	-39	-39	N/A
12/31/2023	N/A	-43	-33	-32	N/A
9/30/2023	N/A	-45	-31	-30	N/A
6/30/2023	N/A	-36	-29	-29	N/A
3/31/2023	N/A	-33	-28	-27	N/A
12/31/2022	N/A	-32	-25	-25	N/A
9/30/2022	N/A	-27	-23	-22	N/A
6/30/2022	N/A	-25	-22	-22	N/A
3/31/2022	N/A	-24	-23	-23	N/A
12/31/2021	N/A	-24	-23	-23	N/A
9/30/2021	N/A	-22	-22	-22	N/A
6/30/2021	N/A	-20	-19	-19	N/A
3/31/2021	N/A	-17	-15	-15	N/A
12/31/2020	N/A	-15	-14	-14	N/A
9/30/2020	N/A	-15	-13	-13	N/A
6/30/2020	N/A	-15	-13	-13	N/A
3/31/2020	N/A	-14	-12	-12	N/A
12/31/2019	N/A	-14	-12	-12	N/A
9/30/2019	N/A	-15	N/A	-12	N/A
6/30/2019	N/A	-16	N/A	-11	N/A
3/31/2019	N/A	-16	N/A	-11	N/A
12/31/2018	N/A	-15	N/A	-11	N/A
9/30/2018	N/A	-17	N/A	-12	N/A
6/30/2018	N/A	-15	N/A	-11	N/A
3/31/2018	N/A	-16	N/A	-11	N/A
12/31/2017	N/A	-15	N/A	-11	N/A
9/30/2017	N/A	-15	N/A	-11	N/A
6/30/2017	N/A	-14	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-9	N/A	-8	N/A
9/30/2016	N/A	-3	N/A	-7	N/A
6/30/2016	N/A	-2	N/A	-7	N/A
3/31/2016	N/A	-2	N/A	-8	N/A
12/31/2015	N/A	-5	N/A	-8	N/A
9/30/2015	N/A	-10	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CLRB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CLRB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CLRB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CLRB来年は収益がないと予測されています。

高い収益成長: CLRB来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CLRBの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/04/06 07:10
終値	2026/04/06 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cellectar Biosciences, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。5

アナリスト	機関
Kumaraguru Raja	Brookline Capital Markets
Keith Markey	Griffin Securities
Aydin Huseynov	Ladenburg Thalmann & Company

Cellectar Biosciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 29% to US$33.33

Price target decreased by 48% to US$4.00

Price target decreased by 26% to US$5.67

No longer forecast to breakeven

Price target increased by 23% to US$14.75

Forecast to breakeven in 2026

Recent updates

Late Stage Radiopharmaceutical Catalyst And Global IP Platform Will Transform Future Cancer Treatment Prospects

Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve

Price target decreased by 29% to US$33.33

Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook

Cellectar Biosciences, Inc. to Report Fiscal Year 2025 Results on Mar 04, 2026

Cellectar Biosciences Expands Global Intellectual Property Estate

Cellectar Biosciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Cellectar Biosciences, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

Cellectar Biosciences Presents Positive Preclinical Data in Poster Presentation At the American Association for Cancer Research Special Conference on Pancreatic Cancer Research

Cellectar Biosciences Announces Iopofosine I 131 as A Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm)

Cellectar Biosciences, Inc. Presents Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Cellectar Biosciences, Inc. to Participate At Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions At the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

New major risk - Financial position

Cellectar Biosciences, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Cellectar Biosciences, Inc. has completed a Composite Units Offering in the amount of $5.999997 million.

New major risk - Market cap size

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

New major risk - Shareholder dilution

Cellectar Biosciences Provides Update on Clover-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Price target decreased by 48% to US$4.00

Cellectar Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $2.5 million.

Cellectar Biosciences, Inc. Grants U.S. Fda Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia

Cellectar Biosciences, Inc. to Report Q1, 2025 Results on May 13, 2025

Cellectar Biosciences, Inc., Annual General Meeting, Jun 13, 2025

New major risk - Financial position

Cellectar Biosciences, Inc. to Report Fiscal Year 2024 Results on Mar 13, 2025

Price target decreased by 26% to US$5.67

Insufficient new directors

Cellectar Biosciences Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Cellectar Biosciences, Inc. announced delayed 10-Q filing

Cellectar Biosciences, Inc. to Report Q3, 2024 Results on Nov 18, 2024

Cellectar Biosciences, Inc. to Present New Data from Phase 2 CLOVER -WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Regains Compliance with Nasdaq Listing Rule 5250(c)(1) Regarding Filing of Form 10-Q

Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Cellectar Biosciences, Inc. Announces Positive Results Data from its Ongoing CLover WaM Pivotal Study Evaluating Iopofosine I 131 for the Treatment of Relapsed/Refractory Waldenstrom's Macroglobulinemia

Insufficient new directors

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

Price target increased by 23% to US$14.75

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

Price target decreased by 7.7% to US$12.00

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

New minor risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical